These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23795561)

  • 1. The formulation of a nasal nanoemulsion zaleplon in situ gel for the treatment of insomnia.
    Hosny KM; Banjar ZM
    Expert Opin Drug Deliv; 2013 Aug; 10(8):1033-41. PubMed ID: 23795561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain Targeted Intranasal Zaleplon Nano-emulsion: In-Vitro Characterization and Assessment of Gamma Aminobutyric Acid Levels in Rabbits' Brain and Plasma at Low and High Doses.
    Abd-Elrasheed E; El-Helaly SN; El-Ashmoony MM; Salah S
    Curr Drug Deliv; 2018; 15(6):898-906. PubMed ID: 29189154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: preparation, characterization, and in vivo evaluation.
    Hosny KM; Hassan AH
    Int J Pharm; 2014 Nov; 475(1-2):191-7. PubMed ID: 25178831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zaleplon loaded bi-layered chronopatch: A novel buccal chronodelivery approach to overcome circadian rhythm related sleep disorder.
    Farag MM; Abd El Malak NS; Yehia SA
    Int J Pharm; 2018 May; 542(1-2):117-124. PubMed ID: 29526622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge.
    Janga KY; Jukanti R; Velpula A; Sunkavalli S; Bandari S; Kandadi P; Veerareddy PR
    Eur J Pharm Biopharm; 2012 Feb; 80(2):347-57. PubMed ID: 22041602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients.
    Khalifa MKA; Salem HA; Shawky SM; Eassa HA; Elaidy AM
    Drug Deliv; 2019 Dec; 26(1):1243-1253. PubMed ID: 31752566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid oral transmucosal delivery of zaleplon-lavender oil utilizing self-nanoemulsifying lyophilized tablets technology: development, optimization and pharmacokinetic evaluation.
    Ali SA; Alhakamy NA; Hosny KM; Alfayez E; Bukhary DM; Safhi AY; Badr MY; Mushtaq RY; Alharbi M; Huwaimel B; Alissa M; Alshehri S; Alamri AH; Alqahtani T
    Drug Deliv; 2022 Dec; 29(1):2773-2783. PubMed ID: 36036168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of insomnia with zaleplon, a novel sleep medication.
    Doghramji PP
    Int J Clin Pract; 2001 Jun; 55(5):329-34. PubMed ID: 11452683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain-targeted intranasal zaleplon solid dispersion in hydrophilic carrier system; 2
    Abd-Elrasheed E; Nageeb El-Helaly S; El-Ashmoony MM; Salah S
    Drug Dev Ind Pharm; 2018 May; 44(5):741-749. PubMed ID: 29235903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, In-vitro, Ex-vivo, and Pharmacokinetic Study of Lasmiditan as Intranasal Nanoemulsion-based In Situ Gel.
    Jaber SH; Rajab NA
    Pharm Nanotechnol; 2024 Jan; ():. PubMed ID: 38173066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
    Dudhipala N; Janga KY
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats.
    Noguchi H; Kitazumi K; Mori M; Shiba T
    J Pharmacol Sci; 2004 Mar; 94(3):246-51. PubMed ID: 15037809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ gels of Metoclopramide Hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits.
    Mahajan HS; Gattani S
    Drug Deliv; 2010 Jan; 17(1):19-27. PubMed ID: 19958151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation.
    Balakumar K; Raghavan CV; selvan NT; prasad RH; Abdu S
    Colloids Surf B Biointerfaces; 2013 Dec; 112():337-43. PubMed ID: 24012665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buspirone Hydrochloride Loaded In Situ Nanovesicular Gel as an Anxiolytic Nasal Drug Delivery System: In Vitro and Animal Studies.
    Abdelnabi DM; Abdallah MH; Elghamry HA
    AAPS PharmSciTech; 2019 Mar; 20(3):134. PubMed ID: 30830481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric nanoencapsulation of zaleplon into PLGA nanoparticles for enhanced pharmacokinetics and pharmacological activity.
    Haggag YA; Abosalha AK; Tambuwala MM; Osman EY; El-Gizawy SA; Essa EA; Donia AA
    Biopharm Drug Dispos; 2021 Jan; 42(1):12-23. PubMed ID: 33320969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profile of SKP-1041, a modified release formulation of zaleplon.
    Greenblatt DJ; Harmatz JS; Walsh JK; Luthringer R; Staner L; Otmani S; Nedelec JF; Francart C; Parent SJ; Staner C
    Biopharm Drug Dispos; 2011 Dec; 32(9):489-97. PubMed ID: 21935965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations.
    Cho HJ; Ku WS; Termsarasab U; Yoon I; Chung CW; Moon HT; Kim DD
    Int J Pharm; 2012 Feb; 423(2):153-60. PubMed ID: 22209996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-Nanoemulsifying Drug Delivery System of Coenzyme (Q10) with Improved Dissolution, Bioavailability, and Protective Efficiency on Liver Fibrosis.
    Khattab A; Hassanin L; Zaki N
    AAPS PharmSciTech; 2017 Jul; 18(5):1657-1672. PubMed ID: 27677262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of intranasal delivery of nanocrystals in powder form on the improvement of zaleplon performance:
    Latif R; Makar RR; Hosni EA; El Gazayerly ON
    Drug Dev Ind Pharm; 2021 Feb; 47(2):268-279. PubMed ID: 33501862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.